The mean of analysts' price targets for Staar Surgical (STAA) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales we
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
STAAR Surgical Company (NASDAQ:STAA ) Q2 2024 Earnings Conference Call August 7, 2024 4:15 PM ET Company Participants Brian Moore – Vice President of Investor Relations Tom Frinzi - Chair of the Boa
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall S
Staar Surgical (STAA) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.40 per share a year ago.
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre

Top 4 Stocks With Notable Insider Buying

09:34am, Friday, 07'th Jun 2024
Insider buying, where company executives or board members purchase shares of their own company, can be a significant indicator for investors. It often suggests that those closest to the company's oper
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STAAR Surgical Company (NASDAQ:STAA ) Q1 2024 Results Conference Call May 7, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Cal
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street e
Beyond analysts' top -and-bottom-line estimates for Staar Surgical (STAA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE